Status:
TERMINATED
Aspirin Resistance Following Coronary Bypass Surgery
Lead Sponsor:
Sheba Medical Center
Conditions:
Ischemic Heart Disease
Eligibility:
All Genders
30-90 years
Phase:
NA
Brief Summary
Aspirin was proved to be the drug preventing vein grafts from closure and improving clinical outcome after coronary artery bypass surgery. It appears to be effective when being prescribed as early as ...
Eligibility Criteria
Inclusion
- Patients undergoing Coronary artery bypass surgery
- Patients who signed Informed Consent Form
Exclusion
- Concomitant valve surgery or carotid surgery or off-pump surgery
- Need for anticoagulation therapy for any reason
- Another antiplatelet medications at least 7 days prior to surgery
- Contra-indication for aspirin treatment
- Thrombocytopenia / thrombocytopathia
- NSAIDs treatment for chronic medical conditions
- Reluctance to participate in the study
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00260377
Start Date
January 1 2005
End Date
December 1 2006
Last Update
September 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel